Full Press Release Details
Eyenovia, Inc. Announces Proposed Public Offering of Common
NEW YORK, NY - July 10, 2019 -
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose
therapeutics utilizing its patented piezo-print technology, today announced that it intends to offer and sell shares of its
common stock in an underwritten public offering. In connection with this offering, Eyenovia expects to grant the underwriters
a 30-day option to purchase up to an additional 15% of the shares of common stock to be sold in the offering. The offering is
subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Eyenovia intends to use the net proceeds from the public offering,
together with other available funds, for the MicroProst and MicroPine clinical studies and for working capital and general corporate
Oppenheimer & Co. Inc. is acting as sole book-running manager
for the offering. Ladenburg Thalmann & Co. Inc. is acting as lead manager for the offering.
The offering is being made pursuant to a shelf registration
statement on Form S-3 (File No. 333-229365) that was declared effective by the Securities and Exchange Commission (the "SEC")
on February 12, 2019. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available
on the SEC's website, located at www.sec.gov. Copies of the preliminary prospectus supplement
and the accompanying prospectus relating to the offering, when available, may also be obtained from Oppenheimer & Co. Inc.,
Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY, 10004, by telephone at (212) 667-8055,
or by email at EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or
a solicitation of an offer to buy these securities nor shall there be any offer or sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology. Eyenovia's
pipeline is currently focused on the late-stage development of microdosed medications for mydriasis, myopia progression, glaucoma
and other eye diseases.
Forward-Looking Statements
Except for historical information, all of the statements,
expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements
include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or
any other statements relating to our future activities or other future events or conditions. These statements are based on
current expectations, estimates and projections about our business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to
predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or
forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file
with the SEC. In addition, such statements could be affected by risks and uncertainties related to, among other things,
market conditions, the satisfaction of customary closing conditions for the proposed offering, the Company's expected
use of the net proceeds from the public offering, its need to raise additional capital even after this financing, and other
risks and uncertainties described in Eyenovia's filings with the SEC. Any forward-looking statements speak only as of
the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake
any obligation to update any forward-looking statements.
Chief Financial Officer
Tram Bui / Alexander Lobo
Phone: 646-536-7035/7037